Asia Avian Flu Market Segmentation, By Strain (H5 Strain, H7 Strain, and H9 Strain), Type (Low Pathogenic Avian Influenza (LPAI) and Highly Pathogenic Avian Influenza (HPAI)), Vaccine (Gallimune/ Gallivac/ Volvac, Nobilis influenza h5n2, Mefluvac, Viraflu and Others), Vaccine Category (Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines, and DNA vaccine), Application (Veterinary and Human), End User (Poultry Farms, Veterinary Clinics, Governmental Organizations, Research Institutes, and Others), Distribution Channel (Direct Tenders, Third Party Distributor, and Retail Sales) – Industry Trends and Forecast to 2031
Africa and Asia Avian Flu Market Analysis
The Africa and Asia Avian Flu market is influenced by various factors, including the recurrent outbreaks of avian influenza in poultry, zoonotic transmission potential, government response measures, and the rising focus on developing vaccines and antiviral drugs. In addition, the avian flu market is also driven by the rising frequency of avian influenza outbreaks and their economic impact on the poultry industry. Increasing government initiatives for disease surveillance and vaccine development further propel market growth.
Africa and Asia Avian Flu Market Size
Africa and Asia avian flu market size was valued at USD 431.40 million in 2023 and is projected to reach USD 778.58 million by 2031, with a CAGR of 7.8% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
Africa and Asia Avian Flu Market Trends
“Government Initiatives and Vaccination Programs”
One notable trend in Africa and Asia avian flu market is the increasing government initiatives and vaccination programs. Governments in Africa and Asia are increasingly recognizing the threat posed by highly pathogenic avian influenza (HPAI) and are taking proactive steps to mitigate its spread. Initiatives include the implementation of comprehensive vaccination programs aimed at poultry populations, which are critical in controlling outbreaks. These programs are often accompanied by awareness campaigns to educate farmers and the general public about the risks associated with avian influenza, proper biosecurity measures, and the importance of vaccination.
Such government-led efforts aim to safeguard public health but also protect the poultry industry, which is a significant contributor to the economy in these regions. By enhancing vaccination coverage and fostering awareness, authorities can reduce the incidence of HPAI, thus minimizing the economic losses associated with disease outbreaks. These initiatives often involve collaboration with international organizations and veterinary experts, ensuring that the programs are well-structured and effective.
For instance, in July 2024, according to an article published by FAO, the Food and Agriculture Organization (FAO) is urging immediate regional collaboration to address the increasing avian influenza cases in the Asia-Pacific region. This call to action comes after a meeting of regional experts in Bangkok, supported by USAID and the CDC. Hence, government initiatives and vaccination programs act as the trend for Africa and Asia avian flu market.
Report Scope Africa and Asia Avian Flu Market Segmentation
|
Attributes
|
Africa and Africa and Asia Avian Flu Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
Afghanistan, Bangladesh, Bhutan, Brunei Darussalam, Cambodia, China, India, Indonesia, Japan, Kazakhstan, Kyrgyzstan, Laos, Malaysia, Maldives, Mongolia, Myanmar, Nepal, North Korea, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Tajikistan, Thailand, Timor-leste, Turkmenistan, Uzbekistan, Vietnam, Rest of Asia, Egypt, Nigeria, Kenya, Algeria, Ethiopia, Morocco, Ghana, Democratic Republic of Congo, Cameroon, Angola, Côte d'Ivoire, Libya, Rwanda, Burkina Faso, Mali, Benin, Namibia, Chad, Mauritius, Madagascar, Liberia, Congo (Rep), Guinea, Botswana, Eswatini, Niger, Malawi, Mozambique, Mauritania, Gabon, Eritrea, Gambia, Lesotho, Comoros, Burundi, Guinea-Bissau, Central African Republic, Cabo Verde, Djibouti, Equatorial Guinea, São Tomé and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe
|
|
Key Market Players
|
Boehringer Ingelheim International GmbH (Germany), Kemin Industries, Inc. (U.S.), Ceva (France), Merck & Co., Inc. (U.S.), China Animal Husbandry Group (China), Sinergium Biotech (Argentina), Qilu Animal Health Products Co., Ltd. (China) among others.
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
|
Africa and Asia Avian Flu Market Definition
Avian influenza, commonly known as avian flu, is an infectious viral disease primarily affecting birds, particularly domestic poultry such as chickens and ducks. It is caused by influenza viruses of the family Orthomyxoviridae, with various strains, some of which can be highly pathogenic and result in severe illness and death among infected birds. Human infections with avian flu can occur, often through direct contact with infected birds or contaminated environments, leading to respiratory illness and, in some cases, severe complications. The disease poses a significant threat to the poultry industry and public health, necessitating ongoing surveillance and control measures.
Africa and Asia Avian Flu Market Dynamics
Drivers
- Rising Incidence of Avian Flu Outbreaks
The rising incidence of avian flu outbreaks in Africa and Asia has significantly heightened the demand for vaccines and treatments aimed at controlling and preventing the spread of the disease. The H5, H7, and H9 strains of avian influenza are particularly prevalent in these regions, leading to widespread concern among poultry farmers, governments, and public health officials. These outbreaks threaten the health of poultry populations and have implications for food security, public health, and economic stability.
For instance, in September 2024, the World Health Organization (WHO) was informed by Cambodia's International Health Regulations (IHR) National Focal Point about a confirmed case of avian influenza A(H5N1) in a 15-year-old child. This case is part of a total of 10 human infections reported in Cambodia in 2024. Since 2003, Cambodia has recorded 72 cases of human A(H5N1) infection, resulting in 43 deaths, with a Case Fatality Ratio (CFR) of 59.7%. According to the IHR (2005), any human infection with a novel influenza A virus subtype poses a significant public health risk and must be reported to the WHO.
Considering the escalating outbreaks, there is a heightened focus on creating and distributing effective vaccines and treatments. Governments and veterinary authorities are prioritizing vaccination programs to combat the risks associated with avian influenza. This increased commitment to disease prevention drives significant investments in research and development, leading to innovations in vaccine technology and production techniques.
- Growth of Poultry Farming Industry
The poultry farming industry in Africa and Asia is rapidly expanding due to rising consumer demand for poultry products and improved production capabilities. As more farms emerge and existing operations scale up, the density of poultry populations increases, creating a higher risk of avian flu outbreaks. This growing risk necessitates robust biosecurity measures and vaccination programs to protect both poultry and human populations from potential infections.
For instance, in May 2024, according to an article published by POULTRY WORLD, in Asia, consumer preferences are shifting toward poultry, which currently accounts for 25% of total animal protein consumption, while seafood constitutes 50% and other animal proteins make up the remaining 25%. This trend indicates a gradual increase in poultry demand. The growth in poultry consumption supports the expansion of the poultry farming industry, driving the need for enhanced biosecurity measures and vaccination programs in the African and Asian avian flu market.
Consequently, the expansion of poultry farming directly correlates with a heightened demand for avian flu vaccines, diagnostics, and biosecurity solutions. Farmers are more inclined to invest in preventive measures to safeguard their livestock and ensure the stability of their operations, while governments and veterinary authorities are likely to support these initiatives to avert outbreaks that could lead to significant economic and health consequences.
Opportunities
- Rising Investments in Poultry Industry
Rising investments in the poultry industry are being fueled by the increasing demand for poultry products in Africa and Asia. As consumers seek protein-rich diets, the sector is modernizing to efficiently meet this demand. This modernization includes adopting advanced farming techniques, enhancing biosecurity measures, and improving overall production capacity. Emphasizing biosecurity is critical, as it helps prevent the introduction and spread of avian influenza among flocks. With better biosecurity practices, poultry farmers are more likely to recognize the importance of vaccination in maintaining flock health and preventing disease outbreaks.
For Instance, in May 2024, according to an article published by WATTPoultry, investors are increasingly optimistic about the poultry industry in South and Southeast Asia, viewing it as a top investment opportunity. It is projected that 55% of global poultry growth will occur in Asia, with 14% attributed to South Asia and another 14% to Southeast Asia, according to data from the USDA and FAO. This anticipated growth in the poultry sector highlights rising investments, creating opportunities for the African and Asian avian flu market as demand for biosecurity measures and vaccination programs increases.
Moreover, increased investment also leads to improved veterinary care services, which are essential for the early detection and management of avian flu. As poultry operations modernize, integrating veterinary services with biosecurity protocols becomes vital. Farmers who invest in better practices are more inclined to utilize vaccines and veterinary care, thereby enhancing the demand for avian flu vaccines and treatments.
- Expansion of Vaccine Portfolios
The expansion of vaccine portfolios through the introduction of innovative vaccines, such as DNA and live recombinant vaccines, presents significant opportunities for companies operating in the avian flu market. These advanced vaccine technologies offer several advantages, including improved efficacy, faster production times, and enhanced safety profiles. For instance, DNA vaccines can be designed to target multiple strains of the avian flu virus, providing broader protection compared to traditional vaccines. Additionally, live recombinant vaccines, which incorporate genes from the avian flu virus into a harmless vector, can elicit strong immune responses, potentially leading to better disease control in poultry.
For instance,
- In April 2024, according to an article published by CureVac SE, CureVac SE has initiated a Phase 1/2 study of its investigational influenza A (H5N1) pre-pandemic vaccine, developed in collaboration with GSK. The H5N1 virus is a potential pandemic threat, occasionally transmitting from birds to humans. This monovalent vaccine uses CureVac’s second-generation mRNA technology to target the H5-antigen. This expansion of vaccine portfolios presents a key opportunity for the African and Asian Avian Flu markets by advancing vaccine options and strengthening preparedness against potential outbreaks
As the demand for effective vaccination programs grows, particularly in regions such as Africa and Asia, these new vaccine offerings can address unmet needs in both veterinary and human health sectors. The increasing incidence of avian flu outbreaks underscores the necessity for advanced vaccination solutions that can mitigate risks not only to poultry but also to public health. Companies that invest in research and development to create these innovative vaccines can gain a competitive edge, catering to the evolving needs of poultry farmers and public health authorities.
Restraints/Challenges
- High Cost of Vaccines and Treatments
The high cost of advanced vaccines and treatments for avian influenza presents a significant barrier to access, particularly in low- and middle-income countries across Africa and Asia. These regions often face economic constraints that limit the funding available for public health initiatives, including vaccination programs. Consequently, many poultry farmers and veterinary clinics are unable to afford the necessary vaccines and treatments, which in turn hinders effective disease control measures.
This financial barrier not only restricts the ability to implement widespread vaccination but also affects overall public health, as outbreaks of avian influenza can have devastating impacts on both animal populations and human health. Additionally, the high costs may lead to reliance on lower-quality or unproven treatments, which can exacerbate the situation by failing to effectively control the disease.
- Rising Emergence of New Strains
The ongoing emergence of new and Highly Pathogenic Avian Influenza (HPAI) strains presents significant challenges for vaccine development in Africa and Asia. These strains, which continuously evolve, can exhibit varying levels of virulence and resistance to existing vaccines. As a result, current vaccination strategies may not offer sufficient protection against these new variants, limiting their effectiveness in controlling outbreaks.
The rapid mutation of the virus strains demands a proactive approach to vaccine development, necessitating research and innovation to create vaccines that can effectively target these emerging pathogens. This situation creates complexities for both veterinary health officials and poultry farmers, as they must continuously adapt their strategies to mitigate the risks posed by these evolving strains. Additionally, the unpredictability of new strain outbreaks can lead to increased economic pressures on the poultry industry, which relies heavily on effective vaccination programs to maintain flock health and productivity.
Africa and Asia Avian Flu Market Scope
The market is segmented on the basis of strain, type, vaccine, vaccine category, application, end user, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Strain
- H5 Strain
- H7 Strain
- H9 Strain
Type
- Low Pathogenic Avian Influenza (LPAI)
- Highly Pathogenic Avian Influenza (HPAI)
Vaccine
- Gallimune/ Gallivac/ Volvac
- Nobilis influenza h5n2
- Mefluvac
- Viraflu
- Others
Vaccine Category
- Inactivated Vaccines
- Live Recombinant Vaccines
- Combination Vaccines
- DNA vaccine
Application
- Veterinary
- Chicken
- Duck and Goose
- Others
- Human
End User
- Poultry Farms
- Veterinary Clinics
- Governmental Organizations
- Research Institutes
- Others
Distribution Channel
- Direct Tenders
- Third Party Distributor
- Retail Sales
Africa and Asia Avian Flu Market Regional Analysis
The market is analyzed and market size insights and trends are provided by country strain, type, vaccine, vaccine category, application, end user, application, end user, and distribution channel as referenced above.
The countries covered in the market are China, Japan, India, Philippines, Indonesia, Bangladesh, Malaysia, Myanmar, Singapore, South Korea, Vietnam, Thailand, Cambodia, Nepal, North Korea, Uzbekistan, Pakistan, Srilanka, Kazakhstan, Tajikistan, Turkmenistan, Laos, Kyrgyzstan, Afghanistan, Mongolia, Timor-Leste, Maldives, Bhutan, Brunei Darussalam, Rest of Asia, Egypt, Nigeria, Kenya, Algeria, Ethiopia, Morocco, Ghana, Democratic Republic of Congo, Cameroon, Angola, Côte d'Ivoire, Libya, Rwanda, Burkina Faso, Mali, Benin, Namibia, Chad, Mauritius, Madagascar, Liberia, Congo (Rep), Guinea, Botswana, Eswatini, Niger, Malawi, Mozambique, Mauritania, Gabon, Eritrea, Gambia, Lesotho, Comoros, Burundi, Guinea-Bissau, Central African Republic, Cabo Verde, Djibouti, Equatorial Guinea, São Tomé and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, Zimbabwe.
China is expected to dominate the market due to advancements in R&D technology and a presence of key players, and surge in R&D expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Africa and Asia Avian Flu Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Africa and Asia Avian Flu Market Leaders Operating in the Market Are:
- Boehringer Ingelheim International GmbH (Germany)
- Kemin Industries, Inc. (U.S.)
- Ceva (France)
- Merck & Co., Inc. (U.S.)
- China Animal Husbandry Group (China)
- Sinergium Biotech (Argentina)
- Qilu Animal Health Products Co., Ltd. (China)
Latest Developments in Africa and Asia Avian Flu Market
- In July 2024, Sinergium Biotech has been launched new initiative to accelerate the development of mRNA vaccines against avian influenza (H5N1) in low- and middle-income countries. Led by Sinergium Biotech, this project leverages the WHO and Medicines Patent Pool's mRNA Technology Transfer Programme. It aims to enhance manufacturing capacity and bolster pandemic preparedness by sharing technology and expertise with partners
- In January 2024, Ceva Santé Animal announced its acquisition of Scout Bio, a leader in pet biotechnology. This strategic move enhances Ceva's innovation capabilities, providing access to a pipeline of monoclonal antibodies and gene therapies for chronic pet diseases. The acquisition aims to accelerate biotherapeutic advancements while continuing Ceva's commitment to all species
- In October 2023, Sinergium Biotech Argentina and PAHO have signed a technical cooperation agreement to enhance RNA technology transfer for vaccine production. During a meeting with PAHO Director Jarbas Barbosa, Health Minister Carla Vizzotti emphasized the importance of this initiative for advancing vaccine development and reducing regional dependence on external technologies. The agreement aims to strengthen the mRNA ecosystem in Argentina, promoting equitable access to health solutions
- In April 2022, Ceva Santé Animale announced a joint venture with Mitsui, forming Ceva Bussan Animal Health K.K. in Japan. This partnership aims to enhance Ceva's presence in the Japanese market, focusing on food safety and disease control in livestock. Leaders from both companies expressed excitement about accelerating development and collaboration in addressing key industry challenges
SKU-